Florence Joly

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Nicoletta Colombo, Cristiana Sessa, Andreas du Bois et al. · Annals of Oncology · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pathology +17

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

Éric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist et al. · Journal of Clinical Oncology · 2010 · 572 citations

Medicine, Oncology, Pharmacology +17

ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

Jonathan A. Ledermann, Xavier Matías‐Guiu, Frédéric Amant et al. · Annals of Oncology · 2024 · 284 citations · Full text

Medicine, Oncology, Pathology +16

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

Christian Pfister, Gwénaëlle Gravis, Aude Fléchon et al. · European Urology · 2020 · 247 citations · Full text

Medicine, Oncology, Urology +14

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Arlindo R. Ferreira, Antonio Di Meglio, Barbara Pistilli et al. · Annals of Oncology · 2019 · 223 citations · Full text

Medicine, Endocrinology, Oncology +15